Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
1.55 p
<0.01 p(0.26%)
At close: 4:00 PM EST
1.55 p
<0.01 p(0.26%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume291.66K
Average Volume (3M)1.23M
Market Cap
£10.62M
Enterprise Value12.21M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.64
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Product StrategyCizzle's concentrated focus on blood-based diagnostics for early lung cancer detection is a durable business-model strength. Specialization can streamline R&D, regulatory pathways and partner interest, increasing the odds of eventual clinical adoption and targeted commercial opportunities if validation succeeds.
Low Financial LeverageNear-zero reported debt materially reduces short-term insolvency risk and gives management optionality on timing of financing or partnering decisions. For a pre-revenue biotech, low leverage is a durable risk mitigant versus peers that rely on debt, preserving strategic flexibility during development.
Lean Operating FootprintA very small headcount implies a low fixed-cost base and operational agility, which can extend runway per pound of cash burn. In early-stage biotechs this structural lean helps preserve capital, supports focused outsourcing, and makes the company a more attractive partner or acquisition target.
Bears Say
Pre-revenue With Persistent LossesBeing pre-revenue with recurring operating losses is a core fundamental weakness: it necessitates continued external funding, increases dilution risk, and constrains reinvestment in R&D or commercialization. Over 2–6 months this structural cash gap will drive financing decisions and strategic dependency on partners.
Equity Turned NegativeNegative shareholders' equity signals capital erosion from accumulated losses and is a durable red flag for solvency perception. It can limit access to non-dilutive financing, raise counterparty concerns, and increase the likelihood that future funding is costly or dilutive, impairing long-term strategic options.
Consistent Cash Burn And Shrinking AssetsOngoing negative operating cash flow and a collapsing asset base indicate the company is depleting its capital foundation. This structural deterioration reduces runway, weakens negotiating power with partners or investors, and increases execution risk for development programs over the medium term.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £10.62M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 82 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.